Readoutin 135d
Sanofi — Isatuximab SAR650984
Phase 3 primary completion: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant.
- Date
- Apr 2027
- Type
- Readout
- Indication
- Plasma Cell Myeloma